Henry Yu
Chief Executive Officer CanWell Pharma
Henry Yu, Ph.D., is the CEO and President of CanWell Pharma, leading the company’s advancement of next‑generation ADCs through its proprietary StarLinker™ platform. Under his leadership, CanWell has progressed multiple innovative ADC programs, including CAN016, a new HER2 dual‑payload ADC that recently received FDA IND approval for advanced solid tumors. A seasoned drug hunter with deep experience across big pharma and biotech, Dr. Yu previously served as a Principal Scientist at EMD Serono. He holds a Ph.D. in Organic Chemistry from the University of Alberta.
Seminars
Wednesday 14th October 2026
Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients
- Laying out CAN016 preclinical profile including monkey tox data supporting dual payload ADC IND approval
- Contextualizing pre-IND filing approach as an emerging ADC modality, and strategy for HER2 refractory patient treatment
- Highlighting ongoing firstin- human development of CAN016 and potential impact in HER2 refractory patients resistant to Enhertu
